Effect of atorvastatin on diabetic retinopathy with hard exudate

Folia Ophthalmologica Japonica

Volumn 57, Issue 4, 2006, Pages 295-300

  Takaba, Teruko ^a   Nishikawa, Norikiyo ^a   Mikajiri, Kenichi ^a   Fukui, Takehiro ^a   Tsukamoto, Yuji ^a   Kawasaki, Yoshimi ^a   Tanaka, Yasuo ^a   Kosugi, Keisuke ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

Author keywords

Atorvastatin; Diabetes Mellitus; Diabetic Retinopathy; Hard Exudate; Hiperlipidemia

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; RETINA EXUDATE;

EID: 33748639514     PISSN: 00155667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. King RC, Dobree JH et al: Exudative diabetic retinopathy, spontaneous changes and effects of a corn oil dies. Br J Ophthalmol 47: 666-672, 1963.
2. Brown GC, Ridley M et al: Lipemic diabetic retinopathy. Ophthalmology 91: 1490-1495, 1984.
3. Klein BEK, Moss SE et al: Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98: 1261-1265, 1991.
4. Cusick M, Chew EY et al: Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 110: 2126-2133, 2003.
5. Gordon B, Chang S et al: The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112: 385-391, 1991.
6. Gupta A, Gupta V et al: Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 137: 675-682, 2004.
7. Jones P, Kafonek S et al: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholosterolemia (The CURVES Study). Am J Cardiol 81: 582-587, 1998.
8. Hunninghake D, Rebecca G et al: Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Family Practice 47: 349-356, 1998.
9. Mason JC, Achmed Z et al: Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 91: 696-703, 2002.
10. Ercan E, Tengiz I et al: Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Kardiol Pol 60: 454-457, 2004.
11. Tan KCB, Chow WS et al: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87: 563-568, 2002.
12. Laufs U, Gertz K et al: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31: 2442-2449, 2000.
13. Bruni F, Pasqui AL et al: Effect of atorvastatin on different fibrinolysis mechanisms in hypercholesterolemic subjects. Int J Cardiol 95: 269-274, 2004.
14. Medicina 31: 1806-1807, 1994.